Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 + T cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8
+
T cells
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-05-08
DOI
10.1002/eji.201948455
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models
- (2019) Steven A. Greenberg et al. Oncotarget
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
- (2019) Tori N. Yamamoto et al. JOURNAL OF CLINICAL INVESTIGATION
- Adoptive Transfer of Interleukin-21-stimulated Human CD8+ T Memory Stem Cells Efficiently Inhibits Tumor Growth
- (2018) Yingshi Chen et al. JOURNAL OF IMMUNOTHERAPY
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Asymmetric PI3K Activity in Lymphocytes Organized by a PI3K-Mediated Polarity Pathway
- (2018) Yen-Hua Chen et al. Cell Reports
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
- (2018) Hannah M. Knochelmann et al. Frontiers in Immunology
- PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
- (2017) Jacob S. Bowers et al. Frontiers in Immunology
- Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies
- (2016) Changchun Deng et al. BLOOD
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- KLRG1 restricts memory T cell antitumor immunity
- (2016) Lei Li et al. Oncotarget
- Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy
- (2015) Christopher A. Klebanoff et al. JOURNAL OF CLINICAL INVESTIGATION
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy
- (2015) Ee W. Su et al. Science Translational Medicine
- Asymmetric PI3K Signaling Driving Developmental and Regenerative Cell Fate Bifurcation
- (2015) Wen-Hsuan W. Lin et al. Cell Reports
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K Signaling in B Cell and T Cell Biology
- (2014) Klaus Okkenhaug et al. Frontiers in Immunology
- Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
- (2013) Madhusudhanan Sukumar et al. JOURNAL OF CLINICAL INVESTIGATION
- Human regulatory T cells induce T-lymphocyte senescence
- (2012) J. Ye et al. BLOOD
- Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
- (2012) L. G. Radvanyi et al. CLINICAL CANCER RESEARCH
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- Determinants of Successful CD8 + T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
- (2011) Christopher A. Klebanoff et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Prolonged Interleukin-2Rα Expression on Virus-Specific CD8+ T Cells Favors Terminal-Effector Differentiation In Vivo
- (2010) Vandana Kalia et al. IMMUNITY
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
- (2009) Luca Gattinoni et al. NATURE MEDICINE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started